The effect of oral L-arginine consumption on uterine artery resistance in women with recurrent implant failure

Determining the effect of oral L-arginine consumption on uterine artery resistance in women with recurrent implant failure

The present study is a randomized clinical trial using a block randomization and double-blind method. Blocks of 4 random number tables are used to allocate individuals to two control and study groups. The sample size was calculated based on similar studies and statistical formulas and was 72 people in total and 36 people in each group.

Research environment : the infertility clinic of Fatemeh Hospital, Hamadan, the research period: 2022-2023. The research population : all infertile women who are candidates for IVF with a history of 2 implantation failures . The research sample: infertile woman who is a candidate for IVF with a history of 2 implantation failures with good quality embryo transfer and a suitable endometrium with the inclusion criteria for the study.

Inclusion criteria: Infertile women aged 18-41 years, candidates for IVF with a history of 2 failures, with a suitable endometrium and good quality embryos, and without chronic diseases, non-smokers, endometriosis, without hormonal disorders, immune disorders, thrombophilia, antiphospholipid antibodies, mutations in factor V, prothrombin, chromosomal disorders. Exclusion criteria: patients with side effects of L-arginine, cancellation of the treatment cycle for any reason, unwillingness to continue participating in the study.

In the intervention group of women with recurrent implant failure and receiving drugs (including: folic acid, vitamin D3, B complex and probiotic) and standard protocol (LONG with suppression) take oral L-arginine supplement from the luteal phase at a rate of 3 g Receive daily for 20 days.

Uterine artery resistance in women IVF candidates with RIF,Successful embryo transfer

The study needs to be updated due to the addition of a series of inclusion and exclusion criteria.

For this purpose, a random block is used. 18 sheets of paper are prepared and the letter A is written on 9 sheets and the letter B is written on the other 9 sheets. The sheets are mixed together and placed in a box and placed in a drawer. And with the reference of each person eligible to enter the study, one of the sheets is randomly taken out and based on whether it is group A or B, it is given to the intervention and control group and the sheets are taken out until every 18 sheets. If it is not pulled out, it will not be returned to the drawer, and after randomly pulling out all 18 sheets, all the sheets will be returned to the drawer and the above operation will be continued up to 4 times on the next 18 patients, ie completing the sample volume to 72.

L-arginine and placebo are exactly the same, and a technician who is not in the research plan prepares the drugs and gives them to the doctor, and the codes remain secret until the end of the research, so the patient and the doctor measure the outcome. And the statistical consultant will not know which group these results belong to until the end of the study and after the disclosure of the codes.